ALKEM2024-10-012024-12-31 ALKEM2024-10-012024-12-31 ALKEM2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member ALKEM2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member ALKEM2024-12-31 ALKEM2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2024-04-01 2025-03-31 2025-02-07 2025-01-28 INR Millions Third quarter 11:00:00 13:40:00 2025-02-07 2025-02-07 Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2024-10-01 2024-12-31 Unaudited Consolidated 33742800000.00 929900000.00 34672700000.00 9240100000.00 3974800000.00 -1171600000.00 6248100000.00 360300000.00 852800000.00 7857500000.00 27362000000.00 7310700000.00 0.00 7310700000.00 1590400000.00 -687600000.00 902800000.00 0.00 6407900000.00 0.00 0.00 0.00 0.00 6407900000.00 121000000.00 6528900000.00 6258200000.00 149700000.00 6378900000.00 150000000.00 239100000.00 2 52.34 52.34 0.00 0.00 52.34 52.34 1.The above unaudited consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'. 2.The above unaudited consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 06 February 2025 and subsequently approved by the Board of Directors at its meeting held on 07 February 2025. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2024. 3.The Board of Directors of the Parent Company at their meeting held on 10 December 2024 have approved the transfer of its Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Parent Company as a going concern on a slump sale basis. The Parent Company is currently in the process of executing Business Transfer Agreement ( BTA ). Since the carve out of the Generic Business Undertaking is to a wholly owned subsidiary of the Parent Company, there is no impact on the consolidated financial results for the quarter and nine months ended 31 December 2024. 4.The comparative financial information of the Group for the quarter and nine months ended 31 December 2023 and for the year ended 31 March 2024, prepared in accordance with Ind AS included in this statement have been reviewed and audited by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information are dated 09 February 2024 and 29 May 2024 respectively. 5. Exceptional item for the year ended 31 March 2024 includes impairment loss of Rs 415.6 Million towards its plant located at Indore. Subsequently, in the previous quarter ended 30 September 2024, the Company as a part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently, related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale. Also, in quarter ended 31 December 2023 a) A cyber security incident which compromised business email IDs of certain employees at one of the subsidiaries resulted in a fraudulent transfer of funds of approximately Rs 513.1 Million which was disclosed as exceptional item for the quarter and nine months ended 31 December 2023. In the subsequent quarter ended 31 March 2024, the Company recovered Rs 290.4 Million out of the above amount and hence amount of Rs 222.7 Million was also disclosed under exceptional item for the year ended 31 March 2024. b) The Group had recognised an additional impairment loss of Rs 576.6 Million in respect of one of the manufacturing units located at St. Louis under S & B Pharma LLC, USA, a step-down subsidiary of the Parent Company, owing to impairment indicators. 6.The Board of Directors at its meeting held on 07 February 2025 have declared an interim dividend of Rs 37 (Rupees Thirty Seven only) per equity share (1850% on the face value of Rs 2 each) for the financial year ending 31 March 2025. 7.The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment information has been made. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 98207700000.00 3477800000.00 101685500000.00 26633400000.00 11340600000.00 -3124200000.00 18375700000.00 932800000.00 2446700000.00 23773600000.00 80378600000.00 21306900000.00 0.00 21306900000.00 4393500000.00 -2016500000.00 2377000000.00 0.00 18929900000.00 0.00 0.00 0.00 0.00 18929900000.00 223100000.00 19153000000.00 18596200000.00 333700000.00 18829500000.00 323500000.00 239100000.00 2 155.54 155.54 0.00 0.00 155.54 155.54 Other Expenses 7857500000.00 Other Expenses 23773600000.00 Remeasurements of defined benefit plans -37600000.00 Remeasurements of defined benefit plans -153800000.00 -37600000.00 -153800000.00 -13000000.00 -50400000.00 Foreign currency translation difference of foreign operations 145600000.00 Foreign currency translation difference of foreign operations 326500000.00 145600000.00 326500000.00 0.00 0.00